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INTRODUCTION
The focus is this study is to test whether a novel molecular diagnostic approach, which we term SH2 profiling, can serve as a useful prognostic tool to classify breast cancer. SH2 domains are small protein modules that bind specifically to tyrosine-phosphorylated peptides. These domains play an important role in normal signal transduction, mediating the formation of multiprotein complexes in response to changes in tyrosine phosphorylation Pawson, 2004) . There are ~116 SH2 domains in the human genome, and different SH2 domains recognize different tyrosine phosphorylated proteins. SH2 profiling is a method in which a battery SH2 domain probes is used to provide a snapshot of the global state of tyrosine phosphorylation in a cell sample (Machida et al., 2003; Nollau and Mayer, 2001 ). Different breast cancers are likely to have different patterns of tyrosine phosphorylation, reflecting differences in the signal transduction pathways active in the tumor, and thus SH2 profiling has the potential to provide a biologically relevant means to classify these tumors. In this project we proposed to test different formats of SH2 profiling (far-western blotting, reverse-phase arrays, histochemical analysis of fixed tumor sections) using breast cancer samples to test the feasibility of these approaches and their potential utility as prognostic tools.
BODY
Task]: Perform SH2 profiling on fresh surgical samples of invasive carcinoma of the breast. Correlate SH2 profile data with standard pathologic criteria and other known molecular markers.
Because of unforeseen difficulties in reconciling the human subjects research protocol approved by the UCHC Institutional Review Board with the requirements of the US Army Human Subjects Research Review Board, human subjects approval for this project was not received until August 2004. Since approval, we have been able to obtain a limited number of surgical samples from the University of Connecticut Health Center and Hartford Hospital. We have to date performed reverse-phase SH2 profiling and ID far-western SH2 profiling on a total of 8 different tumors (for some tumors different histologically distinguishable regions of the same tumor were analyzed separately) as well as two adjacent normal breast tissues.
The reverse-phase far-Western array method (described in detail in Task 2, below) was the primary method used to analyze these breast cancer tumor samples. We have not yet attempted to correlate the resulting SH2 profiling patterns with clinical outcomes due to the low number of samples. However, as detailed below in Task 2c, we have noted in at least one case that the presence of binding sites for a particular SH2 domain (Eat2) correlates with the presence of infiltrating lymphocytes. A goal for the next year will be to profile a larger number of breast cancer samples. To this end we are now collaborating with Dr. Kevin Claffey at UCHC, who has already banked more than 30 additional frozen breast cancer tumor samples, along with associated histological sections. These samples will be profiled along with any additional samples accrued over the next year. Thus by the end of the funding period we should have an excellent sense of the feasibility of using SH2 profiling to classify breast cancers. Task 2a: We have devoted considerable effort to developing and validating a robust, reproducible, and quantitative reverse-phase (RP) far-Western array platform that can be used to generate SH2 profiling data from complex protein mixtures (cell or tissue lysates) as well as purified phosphoproteins. The current assay format (which we term the rosette RP assay) uses a 96-well blotting apparatus. Protein samples are replica-spotted on membranes in register with the wells of the blotting apparatus, and then each well is incubated with a different SH2 domain probe. Thus the relative binding of many SH2 domains can be quantified for each sample. In the past year we have dramatically increased the throughput of this assay format by spotting an array of up to 20 protein samples per well. Thus on a single membrane, more than 1900 quantitative data points can be generated (for example, 120 different protein samples (6 wells) can be tested simultaneously for binding to 16 different SH2 domain probes).
Small amounts of protein (generally less than 1 ng and 400 ng total using a 96-well chamber plate. Pervanadate (POV)-treated HepG2 and v-Ablp w transformed 3T3 samples were used as internal controls for each well. Samples were protein) were analyzed to also probed with anti-phosphotyrosine antibody (anti-pTyr) and anti-actin antibody.
ensure signals were in the Signal was detected by ECL.
linear range. Other controls included a GST 6 probe (negative control for nonspecific binding of GSH-HRP-labeled probe to protein lysates), anti-pTyr (positive control for detection of phosphotyrosine in cell lysates), and anti-actin (positive control for spotting of cell lysates).
Reproducibility is a critical concern in the A B development of molecular diagnostic assays, thus we have extensively ..... 2 validated the rosette RP array system. We 5.1ylaO, 2510% have found that inter-spot and inter-assay , 5 .
5ysate, 25ng
coefficients of variation range from 8.5% inter-spot reproducibility were determined by immunoblotting with and a much smaller number of anti-actin antibody. Identical aliquots of whole cell lysate were phosphotyrosine-binding PTB domains immobilized on nitrocellulose membrane as shown diagrammatically (Pawson, 2004) . During this past year we at top. B: Inter-assay reproducibility was tested in four independent have generated new GST fusions for 45 assays with three GST-SH2 domain probes. C: Coefficient of previously unavailable SH2 domains, as variation (%CV) ranges from 12.9-31.8% for inter-spot reproducibility well as three PTB domains. Thus we now and 8.5-42.4% for inter-assay reproducibility, have in the laboratory GST fusions for 94 out of 116 known SH2 domains (>80%), and the remaining 22 are currently under construction. By the end of the funding period, therefore, we should have in hand the entire complement of human SH2 domains for use in SH2 profiling.
Task 2b:
We have not yet tested the miniaturization of this assay to a microarray (nitrocellulose-coated slide) format because the throughput of the established rosette RP format is sufficient for the number of clinical samples now available. The current format can also more easily accommodate large numbers of different SH2 probes (up to 96 at one time), whereas a slide-based microarray would require a separate slide for each probe, leading to lower throughput and reliability, and higher cost. Thus we felt that the effort to establish the 5 
Task 2c:
We have analyzed tissue lysates from eight surgical breast cancer samples, plus two adjacent normal samples. For one tumor (#113), lysates were prepared from two sections of the same tumor, one of which exhibited significant infiltration by inflammatory cells (lesion 2). Duplicate samples were profiled using the rosette RP assay described above in Task 2a using 48 different SH2 or PTB domain probes, plus antiphosphotyrosine and anti-actin controls. Results are shown in Fig. 3 . As can be readily seen, different SH2 domains vary widely in their binding patterns to tumor lysates, and more importantly different breast cancer samples exhibit different patterns of SH2 binding. In order to group the tumor samples based on similarity in their SH2 binding patterns, background-corrected quantitative binding data were then analyzed using a hierarchical clustering algorithm (Cluster v2.11 (Eisen et al., 1998 ) with "average linkage clustering" settings).
The result was visualized as a "heat map" using Java TreeView (Saldanha, 2004) (Fig. 4) . Clustering and bioinformatics studies were done in collaboration with Dr. Dong-Guk Shin and colleagues in the Department of Computer Engineering at UConn-Storrs.
While the number of tumor samples is too low to draw any general conclusions regarding the significance of SH2-based clustering, we feel that the data are promising in several ways. First, all breast tumors do not have similar profiles, and it is clear that some are quite distinct (for example, tumor #100, and tumor #113 lesion 2), suggesting they might have distinct biological properties. Tumor #113 is particularly interesting, in that two separate lesions of the same tumor were profiled. One particularly striking feature was very strong binding of the Eat2 SH2 to the lesion 2 lysate, whereas virtually no binding for this probe was seen for lesion 1. This result was confirmed by ID far-Western blotting analysis with the Eat2 SH2 probe (Fig. 5) . A very strong Eat2 SH2-binding band is seen for tumor #113 lesion 2, which is absent for the other tumor and normal samples. "When frozen sections of lesions 1 and 2 from tumor 113 were examined by traditional histochemical staining, it is apparent that large numbers of infiltrating lymphocytes were present in lesion 2, but were largely absent in lesion 1 (Fig. 5) SH2 domain function relies on two principles, tyrosine (which contains two SH3 domains in addition to one SH2 phosphorylation dependency and ligand specificity, whose domain) functions to recruit the downstream regulators SOS structural basis is well understood. An SH2 domain consists and GabI following receptor tyrosine kinase (RTK) of -100 amino acids with two a-helixes and seven [3-activation. In this example, the Grb2 SH2 domain binds to strands, ordered [3a[ [31113, with a central anti-parallel P'-sites on the autophosphorylated RTK, leading to Ras sheet flanked by ct-helices [23] (Fig. 1) . Tyrosine-phosactivation via SOS, which is bound to the N-terminal SH3 phorylated ligand peptides are recognized by two key domain, while the P13 kinase-Akt pathway is activated via regions, one the pTyr binding site (referred as the pTyr Gabl, which is bound to the C-terminal SH3 domain [10] .
pocket), and a so-called "specificity determining region" When the other domains include an inhibitory module, as in which interacts with ligand residues C-terminal to pTyr. the case of Cbl or SOCS, SH2-containing proteins can also Based on X-ray crystal structure studies of the Src and Lck act as negative regulators of signaling (discussed below, SH2 domains bound to high affinity ligands, the typical SH2 Section 2).
binding mode has been likened to a two-pronged plug In addition to relocalizing proteins to specific sites engaging a two-holed socket, where the peptide backbone is (binding in trans), interplay between an SH2 and other extended and the side chains of pTyr and the Y+3 residue domains in the same molecule (in cis) can also be important.
each project deeply into complementary pockets on the SH2 SH2 domains of the Src and AbI families of nonreceptor surface [24, 25] . Different binding modes have also been tyrosine kinases engage in intramolecular interactions that observed; for instance, the Grb2 SH2 prefers ligands with a maintain the kinase in an inactive configuration [112] .
[?,-turn conformation of the peptide backbone, in which the Association of the SH2 domains with extrinsic ligands Y+2 Asn residue plays a critical role [6, 26] (various binding relieves the autoinhibitory interaction, triggering catalytic modes are reviewed in Ref. [27] ). activation. Similarly, activation by SH2 domain ligands has Although the two-pronged model is a useful description been reported for proteins containing tandem SH2 domains of SH2 binding, the binding energies conferred by the pTyr [24] . (C) Phosphopeptide preferences of SH2 domains. Sequence preferences of SH2 domains described above were determined by combinatorial phosphopeptide library screening [6,7,59,61.109,165,255----258], mutagenesis [259.266] or structural analysis [106] . Positions are denoted as N-terminal (-3, -2, -1) or C-terminal (+1, +2, +3, +4, +5) relative to pTyr (0). X, any amino acid; (1, hydrophobic amino acid. n.d., not determined (this position was not randomized or mutated in relevant reports).
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pocket and the specificity-detemining region are not lated ligands are available for such domains, their memberequivalent. It is appropriate that the pTyr-dependent ship in the SH2 family remains tentative. interaction should dominate, to ensure that the domain acts Relative to single SH2 domains, the bidentate binding of as a phosphorylation-dependent molecular switch. As a tandem S1-2 domains to bisphosphorylated peptide ligands consequence, the selectivity of a single SH2 domain for its (as in the binding of the p85 subunit of P13K to activated cognate peptide motif is not absolute. The in vitro PDGFf receptor doubly phosphorylated on Y740 and dissociation constant for binding of an SH2 domain to its Y751) confers substantially higher affinity and specificity. preferred pTyr peptide ranges from 0.2 to I gM, over four Such an arrangement may indicate a requirement for orders of magnitude greater than the affinity for the unambiguous molecular recognition to elicit the appropriate unphosphorylated counterpart, but only moderately higher biological response [49] . The increased specificity of (-30-150-fold) than for nonspecific pTyr peptides [6,28... multivalent binding can also be seen when SH2 domains 31]. It is important to remember that physiologically act in concert with other binding module(s), for example an relevant ligands may not necessarily conform to the SH3 domain, to trap a ligand that bears binding sites for "optimal" high-affinity ligands obtained from in vitro both domains [50.52] . screens [32] . Moderate-specificity interactions can be Taken together, it is apparent that SH2 domains are favored by high local concentration, or by the interaction diverse and versatile in nature, capable of either promiscuof other domains of the two partners. In other cases, ous or strict specificity depending on the modular domain recognition of overlapping sets of target peptides by SH2 arrangement and cellular context. It is worthwhile discusdomains may be important to allow signals to amplify or sing in greater detail a few specific cases that illustrate these diverge, creating multiplexed signaling networks, diverse functions. Thus, in the next section we describe The peptide binding specificity of an SH2 domain can recent work on three interesting families of SH2 proteins: be switched by point mutation of a key residue in the SAP, Cbl and SOCS. In the section that follows, we specificity determining region [33.35] . For instance, a Thr highlight efforts to develop pharmaceutical SH2 inhibitors to Trp mutation at residue EF1 of the Src SH2 converted targeting PTK signaling in human disease. its peptide preference to that of Grb2 [34] (here and throughout, the established nomenclature for SH2 domain residues is used, where strands and helices are denoted by 2. SH2 domains in signal transduction letter; see Fig. 1 ) [25] . More recently, it has been suggested that many SH2 domains, including the unmu-2.1. SH2 domain as blocker or adaptor? tated Src SH2, are able to bind quite well to typical Grb2 ligands [36] ; however, in the case of the Grb2 SH2, the X-linked lymphoproliferative disease (XLP) is a recespresence of the bulky Trp side chain prevents binding of sive hereditary disorder characterized by inadequate extended peptides and thus selects exclusively for poYxNx immune response to Epstein-Barr virus (EBV) infection, motifs that adopt a f,-turn confirmation [35] . Thus, SH2 resulting in organ damage and death [53] [54] [55] . Abnormal T binding specificity and binding mode appear to be more cell, B cell, and NK cell responses to virus infection have flexible than initially thought. Indeed, although SH2 been reported in XLP, yet the mechanism of molecular binding is entirely dependent on tyrosine phosphorylation pathogenesis has been elusive [55] . In 1998, three different in most cases, ligands lacking pTyr have also been groups independently identified the same gene (variously reported, including serine-or threonine-phosphorylated named SAP/SH2D]A/DSHP) which is mutated in XLP sites [37.40] , phosphatidylinositol 3,4,5-trisphosphate [42, 56, 57] . Surprisingly, the gene product SAP consists [19, 41] , and unphosphorylated ligands [42.45] . This almost entirely of a single SH2 domain, flanked by a mere suggests that some SH2 domains might have evolved in five N-terminal and 26 C-terminal residues lacking any an ad hoc fashion to recognize, with moderate affinity, recognizable functional motifs ( Fig. 2A) . In T cells, SAP various negatively charged ligands.
was shown to bind to a tyrosine residue (Y281) in the There are multiple examples of relatively divergent or cytoplasmic region of the receptor SLAM/CD150, suggestatypical SH2 sequences, such as the SH2 domains of the ing a role in receptor signaling [42] . Cbl, JAK, and STAT families (Fig. IA) . It has been Unlike typical SH2 domains, the SH2 domain of SAP proposed that SH2 domains can be divided into two groups, can bind the unphosphorylated Y281 site of SLAM with the Src type or the STAT type, on the basis of the secondary high affinity (Kd of 650 nM); the affinity increases only structure of the region between the central anti-parallel P,-four-to fivefold upon phosphorylation [42, 58, 59] . Interestsheet and the cB helix [46] . The latter type is inferred to be ingly, the X-ray crystal structure of the ligand-bound form evolutionarily more ancient. Putative SH2 proteins have of SAP revealed that the binding could best be described as also been found in plants, i.e., Arabidopsis, as well as a a "three-pronged plug and socket," with three distinct more divergent type in yeast, although dedicated PTKs have regions mediating specific interactions.
Phosphopeptide not yet been identified in these species [46.48] . Until threelibrary screening indicated the consensus motif for SAP dimensional structures in complex with tyrosine-phosphorybinding is TlpoYxx(V/I) (where x represents any amino the ligand with GluaA6 and with a buried water molecule. suggested that any one of the three was dispensable for Second, the unphosphorylated Tyr residue associates with high-affinity binding, as long as the other two determinants ArgP1B5 (the "FLVRES" arginine, which is conserved in matched the consensus [58.61] . Consistent with this, the the pTyr pocket of almost all SH2 domains) via ordered tyrosine residue of the SLAM Y281 peptide can be replaced water molecules instead of the usual phosphate oxygens. by any amino acid [61] ; however, it should be noted that Interestingly, EAT-2, a molecule closely related to SAP, physiological ligands without tyrosine at the corresponding also binds the Y281 SLAM peptide in a three-pronged residue have not yet been identified, fashion. However, in this case binding is more phosphorHow can this unique binding mode be explained ylation-dependent, possibly because the more hydrophobic structurally? The overall structure of SAP is similar to environment of the EAT-2 pTyr pocket relative to SAP other SH2 domains such as Src [24] ; the pTyr-pocket is on (eliminating a buried water molecule) reduces interactions one side of the central anti-parallel [p sheet while a with unphosphorylated tyrosine [62] . Third, the C-terminal hydrophobic groove on the other side interacts with the Chydrophobic pocket is rather flexible and can adopt both terminal part of the ligand peptide. However, three unique open and closed configurations depending on the Cfeatures were seen in the structure of SAP bound to the terminal residues of the ligand. This pocket is closed off SLAM Y281 peptide [59, 61] . First, the residues Nby the EF loop when the groove is not occupied, creating a terminal to tyrosine make specific contacts with the SH2: ridge to accommodate ligand peptides lacking a C-terminal a parallel V3 sheet interaction with strand PD of the "prong."
How then does this simple SH2 protein play an important functions as an adaptor, bridging FynT and SLAM. The role immunoreceptor signaling relevant to XLP? Two mechanism was obscure, however, given the single-domain models have emerged: SAP acts either as a competitor or structure of SAP [69] . as an adaptor (Fig. 3A) . A single SH12 domain may serve as A potential solution to this conundrum was reported a natural competitor for other SH2-containing proteins by simultaneously by three groups in 2003: the SH2 domain preventing their binding to sites such as Y28 1, Y307, and of SAP could be shown by biochemical and structural Y327 of SLAM [63] . SHP-2, a protein tyrosine phosphatase approaches to bind directly to SH3 domain of FynT (PTP) with tandem SH2 domains, has been repeatedly [67, 70, 71] . The binding interface overlaps with the canoncoimmunoprecipitated with SLAM [42, 58, [64] [65] [66] . This ical ligand binding region of the FynT SH3 domain but not interaction is disrupted by co-transfection of SAP, suggestthat of the SAP SH2 domain, and the association was ing that SAP competes with SHP-2 for binding to abolished by mutations in the SH3 domain that inactivate phosphorylation sites on SLAM. Indeed, Y281 and Y327 its binding to canonical proline-rich peptides [70] . The match the peptide consensus for both SAP and SHP-2 (Fig.
FynT SH3 domain does not bind the SAP SH2 via a IC) [59, 61, 67] .
polyproline motif, but instead through a small region of Second, SAP may have an adaptor function. Forced the [F strand and ctB helix; mutation of Arg in the FB expression of SAP induces tyrosine phosphorylation of loop abolished binding to FynT without affecting binding SLAM and coprecipitation of SLAM with SH2-or PTBto SLAM [70, 71] . (Parenthetically, this contrasts with the domain-containing proteins such as SHIP, Dok2, Dokl, other well-characterized example of trans SH2-SH3 Shc, and Ras-GAP. Thus, it appears that SAP may not interaction, in which a canonical SH3 binding mode was compete with these other proteins for binding to SLAM, observed between the Abl SH3 domain and a polyproline but instead facilitates their association to the receptor motif in the long DE loop of the Crk SH2 domain [72] ). [66, 68] . Importantly, this effect requires coexpression of Importantly, binding of SAP to the FynT SH3 domain FynT, a T cell-specific isoform of the Src family tyrosine appears to lead to kinase activation of FynT [73] , kinase Fyn; on the other hand, it is apparently phosphapresumably by abrogating SH3-mediated intramolecular tase-independent, because PTP inhibitors do not alter the autoinhibition as previously observed for other Src family tyrosine phosphorylation level. Moreover, FynT has been tyrosine kinases. shown to bind to SLAM in a SAP-dependent manner.
It should be noted that the two models for SAP function Taken together, these findings strongly suggest that SAP described above are not mutually exclusive [74] . SAP is mutated in XLP patients, there is no obvious SAP may be involved in other SLAM-related receptor correlation between XLP disease phenotypes and SAP pathways. genotypes or the binding spectra of SAP SF12 domains to Mice are not susceptible to EBV infection, so XLP must immunoreceptors [58, 75] . Interestingly, introduction of for now be studied in the less experimentally tractable several disease-specific missense mutations into SAP human system, Although SLAM is generally thought to play attenuates the association of SAP with FynT [67] , suggesta dominant role in mediating T cell cytotoxicity, a recent ing a potential role of this interaction in the disease paper showed very low expression of SLAM and high phenotype.
expression of 2B4 on EBV-specific T cell lines from normal A number of intriguing questions remain. For example, and XLP donors, suggesting a more dominant role for 2B4 what is the biological relevance of the phosphorylationin EBV infection [85] . Interestingly, the T cell lines from independent association of the SAP SH2 with the Y281 EBV-exposed and EBV-non-exposed XLP patients showed site of SLAM? A disease-specific mutant of SAP, T531, different interferon ", production levels following CD3 can bind phosphorylated SLAM as well as wild-type (wt) stimulation. Others found correlations of the expression of SAP but has much lower affinity for the unphosphorylated SLAM, 2B4 and SAP in T cells with clinical and form [58] , suggesting phosphorylation-independent binding immunological features of patients with EBV infection or may be important. However, T531 SAP also has lower tuberculosis [86, 87] . Although XLP pathogenesis appears to affinity for other partners, such as CD84, 2B4 (CD244), be due to a disturbance of the Thl/Th2 cytokine balance, Ly9 (CD229), and FynT, which also may account for more clinically relevant studies are needed. pathogenesis [58, 67] . It will also be very interesting to know how binding of the FynT SH3 domain affects the
Cbl: inhibitor of active PTKs
The proto-oncogene Cbl was originally identified as the partners for SH2 binding sites on the SLAM receptor. Why cellular counterpart of the retroviral oncogene v-Cbl, does SAP apparently compete with some partners for which induces B-cell lymphoma in mice [88] . The v-Cbl binding, such as SHP-2, but not with others such as SHIP?
protein was found to have suffered a large C-terminal A plausible model is that SAP competes with SHP-2 for deletion compared to wt Cbl, which consists of an Nbinding to Y281, but does not affect association of SHIP terminal domain (termed CbI-iN), a proline-rich region, and with Y307 and Y327 [42, 58, [64] [65] [66] . However, in vitro a C-terminus containing multiple potential sites of tyrosine binding data indicate that SHP-2 and SHIP bind equally to phosphorylation (Fig. 2B ). Cbl binds a number of signalthe Y281, Y307, and Y327 sites of SLAM [67] . Possibly ing proteins containing SH2 and SH3 domains such as three-dimensional steric factors affect the accessibility of Crk, Grb2, Src and P13K, and thus was initially thought to SH2 domains to these sites in the intact proteins, serve as an adaptor/scaffold protein [89.92]. However, Alternatively, SHP-2 may regulate binding by dephosphorthree important findings have revealed a very different ylating its SH2 domain binding site, as shown in the case function for Cbl. First, Sli-1, the Cbl homologue of C. of SHP-2 binding to IRS-I [76] . The cytoplasmic domain elegans, was found to act as a negative regulator of of SLAM-related receptors contains a TxYxx(V/I) motif signaling downstream of the Let-23 RTK, indicating an that has been dubbed the immunoreceptor tyrosine-based inhibitory role [93, 94] . Second, Cbl-N was found to switch motif (ITSM), the function of which is proposed to associate with tyrosine-phosphorylated proteins [95, 96] . switch depending on its SH2-containing binding partners, Third, a RING finger motif was identified in the central such as SAP, SHP-2 or SHIP [66, 77] .
part of the protein that could function as an E3 ubiquitin Taken together, data suggest that the seemingly simple ligase [97..99] . These findings led to the hypothesis that structure of SAP belies a complex function: by coupling Cbl functions as a terminator of PTK signaling, mediating FynT to SLAM, it mediates the tyrosine phosphorylation the ubiquitination and subsequent degradation of tyrosineof sites that can recruit SHIP and other SH2 proteins.
phosphorylated proteins (Fig. 3B) . Overexpression of Cbl SAP (but not EAT-2, which appears to lack a FynT induces ubiquitination of RTKs such as EGFR, PDGFR, binding motif) has been shown to play a similar role for CSF-IR and c-MET, and is also shown to inhibit activated other immune receptors such as 2B4/CD244, which nonreceptor tyrosine kinases such as Src [100.105] . contain different spectra of SH2 binding sites [74,78 - The ability of the N-terminal domain to bind tyrosine-80]. Since SLAM can modulate production of Thl-type phosphorylated proteins was explained by the X-ray crystal cytokines such as interferon y/ and tumor necrosis factor stnicture of Cbl-N, which revealed the presence of a [64, 81] , SAP deficiency may lead to abnormal Thl divergent SH2 domain [106] . Although not recognizable responses. Indeed, impaired Th2 differentiation was by sequence analysis, this module has the unmistakable observed in T cells from SAP-/-mice, which manifest features of an SH2 domain, with a few variations (notably up-regulation of interferon y and down-regulation of IL-4, the absence of the pE and Ff strands and of a prominent BG similar to SLAM-/-T cells [82.84] . The IL-4 defect is loop). The larger Cbl-N region, also termed the tyrosine more drastic in SAP-/-T cells, however, suggesting kinase binding (TKB) domain, consists of a four-helix bundle, an EF hand calcium-binding motif, and the SH2 pTyr pocket of the Cbl TKB domain. Nevertheless, both domain (Fig. 2B) . This atypical SH2 domain serves as a biochemical and structural data are consistent with other reminder of the diversity of the SH2 domain family, known physiological ligands for Cbl-N; for instance, which may have further unknown members that can only SrcY416 (DNEpoYTAAQQ) and EGFR Y1045 be recognized by secondary or tertiary structural analysis (LQRpoYSSDPT) match the N-terminal and C-terminal [46] . consensus, respectively (Fig. IC) [114] . In the Cbl-N structure the four-helix bundle and EF Another structural analysis, in this case of the Cbl TKB hand contribute to the pTyr binding pocket of the SH2 domain in conjunction with the RING finger and linker domain, suggesting the three modules cooperatively region, provided further clues to Cbl function [115] . recognize phosphorylated ligands, and indeed point mutaSurprisingly, the RING finger was found to anchor the tion of any one of the three can abolish binding [106] .
TKB domain, and the linker region to stabilize the Interestingly, G306E, a point mutation in the pC strand of association, suggesting that deletion of the linker region the SH2 domain first identified as a loss-of-function may cause dramatic conformational instability of the TKB mutation in Sli-1, abrogates the phosphotyrosine-binding and RING finger [115] . The functional importance of this function of the domain, as well as the down-regulation of region is illustrated by the fact that 70Z-Cbl, which contains RTKs and the transforming ability of v-Cbl [107, 108] . a deletion of only 17 amino acids in the linker region and Based on the structure, it is postulated that substitution of RING motif (Fig. 2B ), acquires oncogenicity [116] . Two glycine with glutamic acid could lead to formation of a tyrosine residues (Y368 and Y371) located in the middle of buried salt bridge with Arg 294 in the conserved FLVRES the linker region appear to be crucial. These tyrosines motif in the 1?,B strand of the S112 domain, preventing its undergo phosphorylation under physiological conditions by interaction with phosphotyrosine.
Src and EGFR, and mutation of Y371 to Phe results in Screening of degenerate phosphopeptide libraries indiimpaired ubiquitination of both PTKs [98, 117] . Presumably, cated a consensus of D(N/D)xpoY for Cbl TKB binding, phosphorylation of Y368 and Y371 causes a conformational revealing the importance of N-terminal sequences and in rearrangement of the TKB and RING domains that particular the Y-2 residue (Fig. [C) [109] . On the other promotes the polyubiquitination of substrates such as Src hand, structural studies of Cbl-N bound to a ZAP- 70 and EGFR [118, 119] . phosphopeptide indicated that the mode of interaction was Src family kinases associate with Cbl via their SH3 similar to that of other SH2 domains, with the pTyr pocket domains, which bind proline-rich motifs of Cbl. Accumuand hydrophobic groove playing key roles. The groove is lating data suggest Cbl can inhibit Src and its relatives by somewhat shallow, but specifically interacts with the Y+3 two distinct mechanisms, one via the RING finger and (Glu) Y+4 (Pro) residues of the ligand. Peptide residues Nanother via the TKB domain [118, 120] . Polyubiquitination terminal to pTyr were poorly ordered in the structure.
of Src requires the kinase activity of Src and phosphorTherefore, there is a discrepancy between biochemical and ylation of Y371 in the linker region of Cbl, but not the Cbl structural data regarding importance of N-terminal and C-TKB domain [117] . On the other hand, Cbl can also terminal residues for ligand specificity.
suppress Src kinase activity by the direct interaction of its This discrepancy can be rationalized by carefully TKB domain with phosphorylated Y416, within the considering the experimental approaches. While randomactivation loop of the Src catalytic domain [117] . Cbl is ized phosphopeptide library screening is a powerful tool to also known to associate with and down-regulate the ZAPdetermine ligand preferences, results can be skewed by the 70 and Syk nonreceptor tyrosine kinases via its TKB use of biased libraries in which particular residues are not domain, though the precise mechanism is not clear randomized. For instance, preference in the Y+4 position [103, 104, 121] . was not determined in the case of Cbl-N. Furthermore, this
The mechanism of cell transformation by oncogenic Cbl method can only provide the relative preference at each is still not fully understood. Given that removal of the RING position, and cannot score the effect of combinations of finger or linker region impairs the inhibitory role of Cbl (by residues at different positions. To address this issue, the abrogating its ubiquitin ligase activity), it was proposed that direct sequencing of preferred peptides by mass spectromv-Cbl may act as a dominant negative, protecting phosetry (MS) has been proposed [110.112] . The importance of phorylated substrates from endogenous Cbl and thereby sequence combinations is supported by the recent identileading to sustained PTK activation and cell transformation fication in the c-Met family of RTKs of an unrelated [122, 123] . In this model, oncogenicity requires both an consensus binding site for the Cbl TKB. A DpoYR (Y1003) intact TKB domain and loss of the RING finger/ubiquitin motif, which clearly does not satisfy the previous Cbl TKB ligase activity. Indeed, mutation of the TKB domain consensus, can bind to the domain and is important for Cblabolishes the transforming activity of v-Cbl [122] . However, mediated down-regulation of the receptor [113] . In this case, the Y371F linker domain mutant of Cbl, which has lost the molecular modeling experiments suggest an intramolecular ability to ubiquitinate EGFR while retaining a functional salt bridge between the Asp and Arg residues of the motif TKB domain, fails to transform. Several other linker domain may stabilize it in a conformation favorable for binding the mutants similarly lose ubiquitin ligase activity yet are non-oncogenic, while others, such as Y371A and AY368, are as of a "SOCS box," which is part of an E3 ubiquitin ligase transforming as 70Z-CbI [124] . These data indicate that complex that can target proteins for degradation via the dysfunction of the RING finger in conjunction with a ubiquitin proteasome pathway [144] . Eight of these, referred functional TKB domain is not entirely sufficient for to here as SOCS proteins, possess an SH2 domain Noncogenicity, suggesting additional regulation involving terminal to the SOCS box (Fig. 2C ) [145.147] . the linker region, e.g., interaction with other SH2-containing Although SOCS proteins are similar in structure, varying proteins or other regulators. On the other hand, it is now mainly in the length of the region N-terminal to the SH2 evident that oncogenic activation of RTKs, as in Tpr-Met domain, their biological functions are diverse [138, 148] . For and v-Fms, correlates with their inability to recruit Cbl as a example, SOCS-1 knockout mice exhibit constitutive result of mutation or deletion of TKB binding sites activation of STAT-i and overexpression of interferon--y-(reviewed in Ref. [125] JAK2 by SOCS-l depends on two short sequences adjacent via SH2-pTyr interactions, and subsequently translocate to to the SOCS-I SH2 [151] [152] [153] . One 12-amino-acid stretch the nucleus, where they induce transcription of cytokine-N-terminal to SH2 domain, termed the Extended SH2 responsive genes [126] . In this system dissociation of STATs Subdomain (ESS), stabilizes the association of SOCS-1 with from the activated receptor is required. This is controlled by the kinase activation loop of JAK2. An additional 12-the affinity of STAT SH2 domain-ligand interactions, such amino-acid N-terminal segment, termed the Kinase Inhibthat the affinity of the reciprocal STAT dimer is higher than itory Region (KIR), is required to inhibit of JAK2 kinase that of the receptor for the STAT SH2 [127] . The importance activity (Fig. 2C) . Interestingly, KIR may act as a of JAKs and STATs for cytokine signaling is indicated by pseudosubstrate for JAK2 [151, 153] . A similar mode of the fact that knockout mice for these genes fail to respond to inhibition has been observed in the Grb7, Grbl0, Grbl4 specific cytokines [128] .
adaptor family proteins, which possess a PH domain and an In addition to activation, suppression and termination of SH2 domain. In the vicinity of their SH2 domains, a region cytokine signaling are also essential for appropriate immune termed BPS (between PH and SH2) or PIR (phosphotyrand inflammatory responses [129, 130] . Negative regulation osine interacting region) binds the kinase domain of insulin of cytokine signaling involves receptor internalization and receptor and suppresses its catalytic activity in cooperation degradation, tyrosine phosphatases, inositol phosphatases, with the SH2 domain [154.156] . Analogous to the autoCbl (see Section 2.2), and Protein Inhibitors of Activated inhibition of Src family PTKs by their own SH2 and SH3 STATs (PIAS) [131.135] . Recently, the SOCS family of domains, the SOCS and Grb7 families thus represent SH2 proteins has been added to this list [. [136] [137] [138] . different modes of PTK inhibition in which the SH2 domain Cytokine-inducible SH2 containing protein (CIS) was the plays a central role [157] . first member of the family identified, as an immediate-early In the case of the SOCS family, further diversity in gene product induced by IL-2, IL-3 and erythropoietin function is provided by SH2 domain specificity. While (EPO) [139] . Upon EPO receptor stimulation, activated SOCS-3 has a similar domain composition to SOCS-1, STAT5 binds the CIS promoter and induces its expression.
the SOCS-1 SH2 binds JAKs rather than receptors, while In a classic negative feedback loop, CIS then binds to the SOCS-3 SH2 binds receptors rather than JAKs [148] . phosphorylated Y401 of the EPO receptor, the binding site
The inhibitory effect of SOCS-1 on leukemia inhibitory for STAT5, thereby suppressing STAT5-mediated signaling factor (LIF) signaling is attenuated by replacement of its [140] . Subsequently, three groups identified proteins similar SH2 domain with that of SOCS-3 [153] . Interestingly, to CIS, termed Suppressor Of Cytokine Signaling-i (SOCS-SOCS-1 loses its inhibitory activity by mutation of the 1), JAK-Binding protein (JAB), and STAT-induced STAT invariant Arg in the conserved FLVRES motif in the OIB Inhibitor-i (SSI-1) [141....143] . We now know that there are strand of the SH2 domain, while SOCS-3 is tolerant to more than 40 molecules in a family defined by the presence this mutation; for most SH2 domains, mutation of this residue abolishes binding to tyrosine-phosphorylated regulation by Y759 is not clear at this moment. Recently, peptides. Taken together, these findings imply important Fischer et al. [172] showed that pre-stimulation of cells with functional difference between SH2 domains specific to IL-6 renders STAT3 activation less sensitive to further particular cytokine pathways.
stimulation with IL-6. Interestingly, this desensitization was Regulation of IL-6/gpl30 receptor signaling by SOCS-3 not observed in SOCS-3-deficient cells, but was unaffected illustrates the complicated interplay between SH2 proteins in cells expressing mutant SHP-2, indicating different and their binding sites. IL-6 stimulation leads to tyrosine qualitative roles for SOCS-3 and SHP-2. Whereas the ILphosphorylation of sites on the cytoplasmic tail of gpl30, 6-induced anti-inflammatory responses of SOCS-3 knockincluding Y767, Y814, Y905, and Y915. All of these sites out macrophages and gpl30Y 7 59F mutant macrophages were match the STAT3 SH2 binding consensus (YxxQ), suggestsimilar [173] , mice lacking SOCS-3 in myeloid cells do not ing the involvement of STAT3 in downstream signaling exhibit the severe RA-like inflammatory disease seen in [158] . On the other hand, Y759 (Y757 in mice) has been gpl30Y 7 59 F transgenics [163, 173, 174] . Thus, SHP-2 and shown to play an important role in inhibition of STAT3 SOCS-3 appear to exert distinct regulatory roles on the signaling and activation of Ras-MAPK signaling, as point STAT pathway in vivo, depending on the particular cell mutation of this residue enhanced the IL-6 response and type. reduced MAPK activation [159--161] . Knock-in mice in which this site is mutated (gpl30Y 7 S 9 F) exhibit T cell hyperresponsiveness and rheumatoid arthritis (RA)-like 3. SH2 domain inhibitors joint disease within the first year of age [162, 163] . The SHP-2 tyrosine phosphatase is known to associate with Because of the important role of SH2 domains in signal phosphorylated Y759 in response to IL-6, suggesting SHP-2 transduction pathways, SH2-mediated protein-protein is the negative regulator [159 161] . Recent data, however, interactions are attractive therapeutic targets [175] . The demonstrate that SOCS-3 also inhibits IL-6 signaling via fact that short pTyr-containing peptides (usually five to six Y759, arguing that inhibition might in fact be due to SOCSamino acids) are sufficient to compete with larger protein 3 rather than SHP-2 [164] . As expected, the SH2 domains of ligands for SH2 domain binding has prompted researchers SHP-2 and SOCS-3 favor similar motifs; Y759 both in academia and industry to develop inhibitors (TVQpoYSTVVH) matches the consensus motifs for both targeting the SH2 domains of clinically relevant proteins, (Fig. IC) [161, 165] . Indeed, in vitro data revealed both including Grb2, Src, Lek, Zap70, PI3K, and STAT3 proteins can bind the Y759 peptide with similar affinity [11, 176, 177] . A major difficulty in designing such (Kd=140 nM for SOCS-3 vs. 170 nM for SHP-2), inhibitors is the concentrated negative charge of SH2 suggesting in vivo competition is likely [165] .
ligands (from phosphate and acidic side chains), which is One study demonstrated that the inhibitory effect of unfavorable for penetrating the cell membrane; in general, SOCS-3 was seen in cells lacking intact SHP-2, while substitution of these negatively charged groups causes a conversely the forced localization of SHP-2 to the memdramatic loss of affinity [178, 179] . Elimination or modbrane in Y759F-expressing cells, in which association of ification of the bridging oxygen of phosphotyrosine (to SOCS-3 is prevented, also had an inhibitory effect [166] .
confer phosphatase resistance) also adversely affects bindOthers also reported independent roles for SHP-2 and ing. Moreover, because the pTyr pocket of the SH2 SOCS-3 in LIF-gpl30 signaling using antisense oligonudomain is so well conserved, any inhibitor with high cleotides [167] . While these data indicate that SHP-2 and affinity to this site cannot be selective for a particular SH2 SOCS-3 independently regulate gpl30 signaling via Y759, domain, unless it also targets specificity-determining the physical and functional interaction of SOCS-3 with regions. For all these reasons, developing high-affinity' SHP-2 has also has been reported [166, 168] . In vitro SH2 inhibitors that are specific, stable, and cell-permeable binding experiments suggest that the SOCS-3 SH2 domain is a formidable challenge. Despite these difficulties, binds Y542 of SHP-2 [166] , but since both molecules however, great progress is being made, and in this section contain SH2 domains and potential tyrosine phosphorylawe review efforts aimed at developing inhibitors of the tion sites, and SHP-2 is known to engage in intramolecular Grb2 and Src SH2 domains. Comprehensive reviews of SH2-pTyr interactions [169, 170] , it is difficult to define the this field are also available [176,180.183] . precise binding mode for the complex. To complicate matters even further, Ras-GAP, an SH2-containing negative 3.] . Inhibition of Grb2 SH12 domain regulator of the Ras pathway, was shown to bind Y221 in the C-terminus of SOCS-3 in response to IL-2, resulting in Since Grb2 is known to play a crucial role in signaling activation of Ras-MAPK signaling [17 1].
from RTKs to the Ras-MAPK cascade [184] , Grb2 SH2 Taken together, signaling downstream of the gp130 inhibitors would be expected to suppress cancer cell receptor is shaped by the tyrosine phosphorylation of growth mediated by activated receptors such as HER2/ binding sites for the SH2 domains of STAT3, SHP-2 and Neu, EGFR, and c-Met. Grb2 is an adaptor protein SOCS-3 (Fig. 3C) . The physiological role of the dual possessing a single SH2 domain flanked by two SH3 domains. Upon RTK activation, the Grb2 SH2 domain terminal to pTyr, e.g., attaching 3-aminibenzyloxycarpreferably binds poYxNx motifs [7] , such as Y317 of Shc bonyl group (3-amino-Z) directly to the N-terminus, and Y1139 of Her2/Neu, thus recruiting the Ras activator also led to dramatic improvements in binding potency SOS to the membrane via the Grb2 SH3 domains (Fig. 4B ). [185, 186] . Crystal structures of the Grb2 SH2 bound to All these substitutions were then combined to generate its cognate peptide ligand have revealed that the ligand novel fý-tum mimicking platforms, which were tested for in adopts a type I fA-tum conformation [26] , whereas more vitro binding affinity and for potency in cell-based assays typical SH2 ligands adopt an extended mainchain con- [176, 180] . One such compound, CGP78850 (Fig. 4C) , is formation [24, 25, 187] (see Section 1). These two unique 200-fold more potent than the parent Ac-poYJN-NH 2 characteristics-the strong requirement for Asn at the peptide, and could block EGFR-Grb2 and Shc-Grb2 poY+2 position of the ligand and the lA-tum backbone interactions in MDA-MB-468 human mammary carcinoma conformation-suggested it would be possible to design cells. More importantly, it also inhibited anchorage-indehighly specific inhibitors for the Grb2 SH2 domain.
pendent growth of these cells, one of the defining properties of tumor cells [193] . CGP78850 was further modified into a 3.1.1. Stepwise substitution ofpo YxN mnotif prodrug in which the pTyr phosphate was esterified to A group from Novartis performed a systematic stepwise improve cell permeability. The prodrug version reverted substitution at each residue of the parent tripeptide Acmorphological transformation of Her2/Neu-expressing NIHpoYIN-NH 2 , the shortest peptide retaining micromolar 3T3 cells and inhibited hepatocyte growth factor (HGF)-affinity to the Grb2 SH2 domain (blocked at the N and C induced tumor cell motility [193, 194] . termini with acetyl and amide groups, respectively) [188] . In this process, each position of the peptide is treated as a 3.1.2. pTvr nimetics and macrocyclization "module" which can be manipulated to mimic binding Burke and coworkers used the lA-turn-mimicking platinteractions observed in the crystal structure [26, 176, 180] form of Novartis (above) as the starting point for two (Fig. 4A) . For instance, the poY+l residue must adopt a additional modifications, namely incorporation of pTyr right-handed 310 helical backbone conformation to stabilize mimetics and macrocyclization of the linear backbone. the type I p-tum and maintain multiple van der Waals Because the cytosol has very high levels of constitutive contacts with the SH2 surface. To meet these criteria, tyrosine phosphatase activity, the stability of the phosphate various a,a-disubstituted amino acids known to stabilize the linkage is a major concern in vivo. Early work indicated that 310 helical conformation were docked by computational substitution of pTyr with phosphonomethyl phenylalanine modeling, and the most favorable were incorporated into the (Pmp), in which the pTyr bridging oxygen is substituted by peptide and tested for binding affinity [189, 190] . Modeling a methylene group, led to a fivefold loss of binding potency predictions were consistent with results from competitive in the case of ligands for the P13K SH2 domain [195] . This binding assays; for example, aminocyclohexanecarboxylic was thought to be due to insufficient ionization of Pmp acid (Ac 6 C), predicted by modeling to have optimal van der (because of its higher pKa relative to pTyr at physiological Waals contacts, had the highest affinity among related pH) or loss of hydrogen bonds between the SH2 and the analogs (Fig. 4B) .
pTyr bridging oxygen [196, 197] . When Pmp was incorpoThe same strategy was employed for other parts of the rated into the lA-turn platform, however, unexpectedly high Ac-poYlN-NH 2 peptide to judiciously substitute peptide affinity was reproducibly observed, comparable to that seen backbone and/or side chains. As Grb2 SH2 strongly favors with pTyr (Fig. 4B ) [180, 198] . This group also tested pTyr Asn at the Y+2 position, any substitution at this position mimetic groups lacking phosphate, such as mono-or must fulfill strict local requirements, including a rigid dicarboxy phenylalanine derivatives, in the l-turn platform backbone to stabilize the l,-turn, preserving specific [199, 200] . The monocarboxy series, e.g., carboxymethylinteractions with the Lysl3D6 and LeulAE4, and steric phenylalanine (cmF, Fig. 4B ), while useful in decreasing the accommodation of TrpEF1 of the Grb2 SH2. cis-2-aminonet negative charge relative to pTyr, decreased affinity by cyclohex-3-ene carboxylic acid (Achec) was selected by almost 100-fold, underscoring the importance of two substructure chemical database screening, and as predicted negative charges for molecular recognition by SH2 the 1S,2R diastereomer could substitute for Asn with little domains. Consistent with this, compounds containing loss of affinity (Fig. 4B) [191] . The strict spatial requiredicarboxy pTyr mimetics such as p-malonylphenylalanine ments for this position are illustrated by the dramatic loss of (Pmf, Fig. 4B ) displayed comparable affinity to those with binding potency seen with its diastereomer (IR,2S)-Achec.
Pmp or pTyr. Because the crystal structure indicated that the C-tenninal In order to stabilize the lA-turn conformation, the Burke part of Ac-poYIN-NH 2 makes van der Waals contacts with a group also attempted to constrain the linear peptide mimetic hydrophobic patch on the surface of the SH2 domain, a by macrocyclization [201] [202] [203] . Surprisingly, although the lipophilic attachment was designed. Appending a Ccyclic analogue exhibited approximately 100-fold enhanceterminal 3-naphthalen-1-yl-propyl functionality improved ment in binding potency in vitro relative to its linear the binding affinity by 25-fold [192] . Modifications Ncounterpart, it was not effective in whole cell assays [201] .
K. Machida However, when the pTyr (x position was modified by a MDA-MB-453 cells (40% growth inhibition at 5 -tM) carboxymethyl (CH 3 CO 2 H) functionality (Fig. 4C, corn - [210] . In addition, a compound incorporating non-phospound 1), this compound not only blocked the association phorylated 3-aminotyrosine was recently reported to have of Grb2 with Her2/Neu in whole cell assays, but also low nanomolar affinity for the Grb2 SH2 [211] . Thus, it is displayed anti-mitogenic effects in MDA-MB-453 cells apparent that there are multiple solutions to the tradeoff [202, 204] .
between the need for negatively charged pTyr mimetics for optimal affinity and the need to minimize charge to 3.1.3. Non-phosphorylated ligand GI facilitate cell entry. Roller and coworkers employed a completely different strategy to identify novel unphosphorylated high-affinity 3.1.4. Impact of N-terminal modifications ligands for the Grb2 SH2 domain [205] . They screened a Although the two different Grb2 inhibitor platforms (the combinatorial peptide phage-display library, where nine p-turn mimicking tripeptide and cyclic peptide GI) were variable amino acids were flanked by cysteine residues (to developed independently, some similarities are apparent promote disulfide-mediated cyclization). From this screen ( Fig. 4C and D) . For instance, incorporating aminothey isolated the cyclic peptide CELYENVGMYC (GI), cyclohexanecarboxylic acid (Ach/Ac6c) into the Y+I which potently blocked binding of the Grb2 SH2 domain to position (which helps stabilize the [I-turn conformation) a phosphorylated Shc Y317-derived peptide (IC 50 =10-and structural constraint via macrocyclization are beneficial 25gM) [205] (Fig. 4D , GITE: thioether-bridged analogue in both cases. It also is noteworthy that modifications Nof GI). GI is not tyrosine-phosphorylated but does contain a terminal to pTyr significantly improve binding affinity for YxN motif. Mutational studies indicated the particular both platforms. An early hint was provided by the importance of this motif, as well as Glu at the Y-2 position observation that a phosphopeptide (EpoYJN-NH 2 ) bearing (Fig. 4D) [205, 206] . Structural analysis suggested that this an N-terminal fluorophore (anthranic group: Abz, Fig. 4B ), cyclic peptide, for which ring closure is critical for binding, which was used as a reference for ELISA-type assays, adopts a p-tum-like confomaation similar to that found in unexpectedly displayed a dramatic enhancement of affinity. natural (pTyr-containing) ligands, but utilizes a larger This led to design of a 3-aminobenzyloxycarbonyl (3-binding surface [206, 207] .
amino-Z) N-terminal group [188] . Structural studies Relative to physiological Grb2 binding sites (e.g., Y317
revealed stacking interactions between the electron-rich in Shc and Y1139 in ErbB2), where the residue at the -2 anthranyl moiety in the ligand and the electron-deficient position is Pro, Glu at this position of GI is unique. A Glu guanidinium group of Arg cLA2 of the SH2 [180, 212] . Nto Ala substitution at this position of G1 caused a dramatic oxalyl modification (COCOOH-) also modestly improved loss of affinity [205, 206, 208] , while, on the other hand, affinity in the p-tum platforn (Fig. 4B ). Molecular substitution with unnatural amino acids containing acidic modeling dynamics simulation studies suggested additional dicarboxylic side chains, e.g., y-carboxyglutamic acid (Gla), electrostatic interactions between the acidic oxalyl funcsignificantly improved binding [208, 209] . Tyrosine phostionality and the positively charged side chain of Arg otA2 phorylation of GI increases binding affinity by more than [198, 199, 213] . 100-fold. Interestingly, in this context an acidic residue at N-terminal modifications also illustrate the complexities the -2 position is no longer beneficial, and the Glu to Ala and subtleties inherent in "rational" inhibitor design. For substitution actually enhances binding, which suggests instance, it is apparent that there are interesting compatcomplementary roles for phosphotyrosine or an acidic ibility issues between specific N-terminal modifications residue at the -2 position. Although no structural comparand pTyr mimetics. For example, the Nea-3-amino-Z ison is yet available, a plausible interpretation is that the modification improves binding for pTyr-containing ligands, carboxyl group of Glu can engage in some of the same but not for Pmp-containing ligands [213] , while the Nuinteractions as the pTyr phosphate. This suggests some oxalyl functionality is compatible with both pTyr and Pmp degree of plasticity in the SH2 domain, allowing multiple [198, 213] . It is also remarkable that N-terminal modificamodes of binding with different ligands.
tion by oxalyl or carboxymethyl (CH 2 COOH-) functionUpon optimizing each position of GI, a high-affinity alities brings an additional negative charge to the Grb2 SH2 inhibitor peptide was produced ( Fig. 4D corresponding inhibitors; despite this, such compounds compound 2; IC 5 o=26 nM) [209] . Importantly, compound are often active in cell-based assays [201, 202] . The affinity 2 effectively inhibited the association of G'b2 with ErbB2 improvement observed in in vitro assays may not entirely in whole cell assays at low micromolar concentrations, account for this effect, since the unmodified counterparts, demonstrating the potential usefulness of non-phosphorywhich are inactive in cell based assays, already bind with lated SH2 inhibitors in vivo [209] . A GI analogue high affinity. containing the pTyr mimetic Pmp (thereby acquiring Importantly, N-terminal modification generates addiadditional negative charge), which was further modified tional binding interactions not observed in the crystal to increase cell permeability by attaching a hydrophobic structure of the Grb2 SH2 bound to peptides derived from carrier peptide, also exhibited anti-mitogenic effects in natural ligands. In the case of the non-phosphorylated cyclic GI peptide, structural modeling analyses indicated 3.2.1. hnportance of the sca/.fbId acidic side chains at the Y-2 position make multiple
The Src SH2 binds to high-affinity ligands via a "twointeractions with arginines and serines at the pTyr pocket pronged plug and socket," where the side chains of pTyr [208] . Do any natural ligands take advantage of similar Nand the Y+3 residue (generally Ile) are buried in distinct terminal interactions? Rojas et al. [214] showed that a pockets [24, 25, 223] . There is no doubt that these two peptide encompassing the Shc-Y317 phosphorylation site regions, with multiple specific contacts, are crucial for the (FDDPSYVNVQNL), which has acidic residues at the Y-3 SH2-ligand association. However, the linker region and Y-4 positions, could inhibit Grb2-Shc interaction when between pTyr and Y+3 (Y+ I and Y+2 residues of a delivered into cells without prior phosphorylation. Thus, peptide ligand) is also important for the design of Src under physiological conditions, it is likely that binding of SH2 inhibitors. This region makes contacts with the Grb2 to sites such as Shc-Y317 would be less dependent solvent-accessible hydrophobic surface of the SH2 domain on tyrosine phosphorylation than more typical SH2 and acts as a scaffold that appropriately orients the pTyr interactions, and Y+3 side chains into their respective pockets [181, 224] (Fig. 5A ). In the crystal structure of the Src
Src inhibition and bone resorption
SH2 domain bound to high affinity peptide, the mainchain of the Y+I residue makes direct contact with HisýD4 of Src is the prototype nonreceptor PTK, and its activation the domain, while the side chains of Y+I and Y+2 are in human tumors such as breast cancer has been reported relatively free [24] . Nevertheless, a series of analogs [215] [216] [217] . Src-deficient mice exhibit osteopetrosis, or containing dipeptides or hydrophobic linkers between pTyr hypertrophy of bones, indicating impaired osteoclast and the Y+3 Ile displayed more than 100-fold lower function [218] . Therefore, antagonizing Src function in affinity than the wild-type peptide [179] . Single amino vivo may inhibit tumor growth and be useful for treatment acid substitutions at Y+l or Y+2 were tolerated relatively of osteoporosis and prevention of osteolytic changes well, but D-amino acid substitution for Y+I caused a related to tumor metastasis. However, because the Src major loss of affinity, indicating the importance of the protein is tightly regulated by multiple domains including backbone conformation in this position [179] . The hydro-SH2, SH3 and kinase domains, the consequences of phobic surface here is mainly formed by TyrpD5, which inhibition of the Src SH2 domain are not entirely is known as a specificity-determining residue [6, 33] . straightforward. Nonreceptor tyrosine kinases generally Mutational studies have shown that substitution of require SH2 domains for efficient substrate phosphorylaTyrp3D5 to Phe results in a 30-fold loss of affinity tion [20] , so SH2 inhibition is likely to suppress [225] . Surprisingly, thils effect is greater than for a phosphorylation and downstream signaling. In addition, it mutation of the conserved ArgcuA2, known to make may suppress kinase-independent adaptor functions mediimportant electrostatic interactions in the pTyr pocket, ated by SH2 and SH3 domains of Src [219] . On the other which results in only a sixfold affinity loss [31] . TyrpD5 hand, Src is nonrmally held in an inactive conformation via makes van der Waals contacts with the side chain of Y+I, an intramolecular interaction between its SH2 domain and forming a platform for the extended ligand peptide a tyrosine-phosphorylated C-terminal residue, Y527. Abrobackbone [24, 225] . Therefore, selection of a scaffold that gation of this interaction leads to activation of the kinase, favorably interacts with this hydrophobic surface is a and Y527 mutants of Src, e.g., Y527F, are known to be critical element in designing inhibitors. transforming. Hence, Src SH2 inhibitors are potentially
The ideal scaffold would provide a rigid backbone, valuable, but any clinical applications must take into preserve existing hydrogen bonds with HisPD4, LysPD6 account the potentially disastrous effects of inappropriate and IlepE4, and make stacking interaction with the activation of Src.
aromatic ring of TyrlD5 [226] . Researchers at ARIAD Nevertheless, Src SH2 inhibitors have great potential to have conducted stnicture-based design studies examining treat osteoporosis. One reason for optimism is that knock-in various types of scaffolds for Src SH2 inhibitors, mice bearing a kinase-inactive K295M Src mutant exhibit including ureido-type peptide mimetics [227] , disubstipartial recovery of the osteopetrosis phenotype, indicating tuted thiazoles [228] , oxazoles [224] and benzamide that the Src SH2 and SH3 domains play a critical role in [229] . Notably, X-ray crystallography revealed the osteoclast function [219] . Until now, osteoporosis has benzamide template forms hydrogen bonds with LysO?,D6, generally been treated with two categories of drugs: bone displacing water molecules found in the previous X-ray resorption inhibitors such as biphosphonate, and stimulants structure. Subsequently, a seven-membered bicyclic benof bone formation, such as parathyroid hormone and zamide scaffold platform, which fully complements the prostaglandin E2 [220] . In recent years, several pharmaconvex surface created by TyrPD5, has been developed ceutical companies including Glaxo, ARIAD and Aventis [226] (Fig. 5B) . Using an alternative approach, researchhave been working to develop Src SH2 inhibitors, with the ers at Aventis selected a caprolactam scaffold and also rationale that Src is a validated therapeutic target for bone confirmed displacement of structured water molecules by resorption [182, 221, 222] .
X-ray crystallography. This platform, incorporating pTyr and biphenyl functionalities, showed 15-fold higher 4'-diphosphonomethyl-phenylalanine (termed as dpmF or affinity than the natural poYEEI peptide [230] . [178] suggested this cysteine is accumulation of these inhibitors in bone matrix followed particularly reactive since the highly basic environment of by uptake into osteoclasts by phagocytosis [181] . Interestthe pTyr pocket lowers the pKa of the sulfhydryl. Therefore, ingly, bisphosphonates themselves are known to inhibit an appropriately positioned electrophile such as an aldehyde osteoclast function and bone metastasis [239, 240] . The group may form a reversible covalent bond with this group osteoclast inhibitory abilities of Dpp-and dpmF-incorpo- [231] . Various Cys PC3-targeting pTyr mimetics including rating SH2 inhibitors, however, depend on their binding Y-fornyl-pTyr, 3'-formyl-4'-Pmp and 3'-formyl-4'-carpotency to the Src SH2 domain [237] . boxy-phenylalanine have been tested. The 3'-formyl-4'-The two classes of Src SH2 inhibitors discussed here, Pmp template did not engage CysFgC3 because of the cysteine-targeting and bone-targeting compounds, disdisposition of the aldehyde group [234] . For the 3'-formylplayed almost equivalent in vitro binding potency pTyr template, X-ray structures confirmed hemithioacetal (IC 50 =0.1-0.4 [tM), while the IC 50 values for the rabbit formation, but no inhibition was observed in cell-based osteoclast resorption assay were very different, 43 [tM for assays. This failure was most likely due to some combinathe cysteine-targeting compound and 2 pM for dpmFtion of loss of affinity through entropic effects at the pTyr incorporating compound [233, 236] . To date, an inhibitor pocket, phosphatase susceptibility, and poor cell permewith both cysteine-and bone-targeting functionalities has ability [231, 232, 234] . not been reported. It is important to note that proof-ofOn the other hand, a 3-formyl-4'-carboxy-phenylalaconcept studies have demonstrated that Src-specific SH2 nine-containing (Fig. 5B, Fcp) SH2 inhibitor, AP22161
inhibitors indeed suppress bone resorption by osteoclasts (Fig. 5C ), showed dramatic improvement in binding [233, [236] [237] [238] . Since Src kinase inhibitors display similar potency. AP22161 was shown to form a hemithioacetal by activity, the functional importance of both the SH2 and the nuclear magnetic resonance (NMR) analysis, dependent on kinase domains of Src in osteoclasts has been convincingly interaction of the formyl group with CyslpC3. It binds the demonstrated [241, 242] . Src SH2 100-fold better than that of Src family member Yes, and 1700-fold better than the more distantly related ZAP-70 3.3. Structure-based design and binding mode SH2s [233] (Fig. 5C) . Moreover, AP22161 inhibited rabbit osteoclast-mediated resorption of dentine and showed It is obvious that computational modeling, taking partial morphological reversion of Src Y527F mutantadvantage of available crystal structure data, plays a key transformed rat fibroblasts [233] . The normal physiological role in the structure-based design of SH2 inhibitors. For role of this highly reactive cysteine is not clear. Mutation of example, inhibitors containing various scaffolds were CysP•C3 causes an eightfold improvement in affinity for docked onto the Src SH2 domain, using the pTyr residue consensus ligands, suggesting a negative role in the pTyr as an anchor based on the known binding mode of pocket [31 ] . In addition, Cys3C3 may play some role in the poYEEI high-affinity peptides, leading to the choice of weak phosphatase activity reported for the Src SH2 domain benzamide scaffolds [229] . However, subsequent X-ray [235] .
crystal structures demonstrated significant differences in the details of the actual mode of binding compared to 3.2.3. Targeting SH2 inhibitors to bone modeling predictions. These differences suggest difficulties Another approach to enhance specificity is to target in de novo prediction of binding mode by computational inhibitors to therapeutically relevant cells or tissues.
modeling, and emphasize the importance of confirmation Therefore, attaching functionalities that specifically target by structural analysis for each SH2 inhibitor [227, 231] . Src SH2 inhibitors to bone might promote the inhibition of Such structural studies sometimes reveal new and unexbone resorption by osteoclasts while minimizing potential pected binding modes, which in turn provide valuable undesirable effects on other cells. To test this concept, two information for further inhibitor design. For instance, bone-directed bisphosphonate-incorporating pTyr mimetics, crystallizing the Src SH2 domain in citrate buffer unexpectedly revealed a citrate ion stacking into the pTyr Imatinib in treatment of chronic myelogenous leukemia and pocket [236] . Interestingly, additional binding interactions other malignancies [248] , achieving a significant survival were seen, e.g., ionic bonds between citrate and Lysf1D6, benefit with new anti-tumor agents remains a daunting that had not been noted in previous structural studies, challenge. Nygren and Larsson [249] recently evaluated leading to the design of new pTyr mimetics such as dpmF publicly available data for a total of 209 investigational antiand Dpp [236] [237] [238] [193] . It able to adopt different binding modes, thereby increasing should be noted, however, that Grb2-SH2 inhibitors may the flexibility of its interactions. This is most likely because block other pathway(s) normally mediated by the SH3 the pTyr pocket can accept phosphate in different orientadomains of Grb2, such as PI3K-Akt cell survival signaling. tions, and also because ordered water molecules can bridge On the other hand, a Src SH2 inhibitor could partially revert between the scaffold or hydrophobic regions of the ligand cell transformation induced by Y527F Src, although a 10-and the rigid surface of the SH2 domain, fold higher concentration was needed relative to the Src kinase domain inhibitor PPI [238] .
Bioavailabilit. of SH2 inhibitors and other challenges
Moreover, a concern with Src SH2 inhibitors is their potential to inappropriately activate Src kinase by competIn light of the major constraints on the bioavailability ing with the autoinhibitory interaction between the Src SH2 of SH2 inhibitors (cell permeability, stability, and antiand the regulatory pTyr. The Aventis group reported that genicity), together with simplicity of synthesis, it is clear several high-affinity Src SH2 inhibitors did not activate that smaller, less charged compounds with minimal Y527-phosphorylated Src in ELISA-based assays and yeast peptidic character are ideal [244, 245] . In terms of size whole cell assays; the reasons for this are unclear [250] . One and peptidic character, Src SH2 inhibitors roughly the approach to this problem might be to design bidentate size of dipeptides have been developed with lipophilic ligands that engage multiple domains of the target protein as scaffolds [182] (Fig. 5) , while the Grb2 SH2 domain a means to enhance specificity and sensitivity [50, 251] . A seems to require larger macrocyclic ligands to achieve tethered compound linking peptides that target the kinase high affinity (Fig. 4) . The issue of negative charge is still active site and the SH2 domain of Src, thereby preventing challenging. Decreasing the charge of pTyr mimetics substrate binding by both the SH2 and catalytic domains improves cell permeability, at the price of decreased without stimulating kinase activity, was shown to enhance affinity for the pTyr pocket. What is the minimum inhibitory potency compared to monovalent active siteacceptable charge for binding to SH2 domains? Beaulieu directed compounds [252] . Despite these remaining unreet al. [246] tested various substitutions for acidic side solved issues, the use of SH2 inhibitors to specifically block chains of a poYEEI-OH peptide for their effect on phosphorylation-dependent protein-protein interactions binding of the Lck SH2 domain, and demonstrated low remains an attractive concept. micromolar affinity for an inhibitor bearing a net charge of -2 at physiological pH. Gratifyingly, the bonetargeting Src SH2 inhibitor (bearing the highly charged 4. Concluding remarks bisphosphonate pTyr mimetic) is effective in cell-based assays; in this case, the disadvantage of high net negative
We have highlighted three SH2-containing proteins and charge is offset by the advantage of bone-specific two groups of SH2 inhibitors to illustrate recent progress in targeting [236 238] . In order to rapidly screen potential understanding both the common features of SH2 domains SH2 inhibitors and drive future development, highand the differences that allow them to be adapted to so many throughput assay platforms that can simultaneously cellular functions. These recent studies reveal a number of evaluate both binding potency and cell permeability will subtle twists on the common and accepted themes of SH2 be critical. The ARIAD group has developed a promising function. For example, previously unappreciated binding mammalian cell assay based on the two-hybrid system modes were discovered, underscoring the plasticity of SH2 and used it to screen a panel of Src SH2 inhibitors domains, which is likely to be relevant to interactions with [238, 247] . physiological ligands. It is now apparent that the SH2 A major rationale for developing both the Grb2 and Src domain features an "adjustable fif' to accommodate various SH2 inhibitors was their potential for treating human ligands, consistent with the notion that a single SH2 domain malignancies. Despite the spectacular recent success of displays only modest specificity for various phosphopep-tides in vitro assays [27] . It is of particular interest to know In addition to helping understand normal cell signaling, 
